Testing a new drug called NRG-103 in people whose high-grade glioma has come back or is growing
Original title: A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find a safe dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a new drug, NRG-103, in people whose high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has returned or is getting worse.
Who this trial is for. This trial is for people with high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that has come back or is progressing. It tests a drug given by injection called NRG-103.
Where it stands. There are no results yet. The trial team is looking for the safe dose range of NRG-103, and for a dose to use in later treatment. They are also taking an early look at how well people tolerate it and how it works. The answers are not in yet, and this trial has not reported results.
What this means, and what it doesn't
What it could mean: For now, this only means a new drug is being tested. It is not something your doctor can prescribe. If this sounds like your situation, you can ask your care team about it. They can tell you if a trial like this makes sense for you.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that it will help you. This is not a promise of a cure.
Source: ClinicalTrials.gov, July 17, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.